NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential ...
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a Phase III study titled ‘A ...
Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.
The approval was based on the C-POST study which evaluated cemiplimab in adults with CSCC at high risk of recurrence after surgery and radiation.
The FDA has approved cemiplimab-rwlc for adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk for ...
The Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback